IgA nephropathy with moderate to severe histological alterations
Conditions
Interventions
Methylprednisolone pulse therapy followed by oral prednisolone administration
Methylprednisolone pulse therapy followed by oral prednisolone and mizoribine administration
Sponsors
West Japan Study Group for Therapy of IgA Nephropathy
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with IgA nephropathy who underwent renal biopsy and provided a written informed consent prior to study by reading and signing the form. 1) Patients who have 5 or more of glomerular score*. 2) Patients who are between 15 and 60 years of age. 3) Patients who have potential to receive methylprednisolone pulse therapy on inpatient basis, and thereafter to receive routine medical treatment as outpatients. *(Katafuchi R et al.Clin Nephrol 49,1998)
Exclusion criteria
Exclusion criteria: 1) Patients who have been treated with corticosteroids or mizoribine already 2) Patients who suffered infectious diseases such as pneumonia 3) Patients whose white blood cells count is under 3,000/mm3 4) Patients who are demonstrated to have another renal disease on renal biopsy 5) Patients who have diabetes mellitus 6) Patients who are have severe heart or liver disease 7) Patients who have malignant tumors 8) Patients who are currently pregnant or are supposed to be pregnant 9) Patients who are judged to be inappropriate for participation in this study by an physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Altered amounts of proteinuria | — |
Secondary
| Measure | Time frame |
|---|---|
| Alteration of serum creatinine (SCr) and the slope of reciprocal SCr | — |
Countries
Japan
Contacts
Public ContactKosuke Masutani
West Japan Study Group for Therapy of IgA Nephropathy Kidney Care Unit, Kyushu University Hospital
Outcome results
None listed